Galectin Therapeutics Inc. announced the appointment of current board member, Joel Lewis, to the position of Chief Executive Officer and President. In this position, Mr. Lewis will set corporate strategy and oversee operations, most importantly the Company’s global NASH-RX adaptively-designed trial for the prevention of varices in NASH cirrhosis patients using its proprietary galectin-3 inhibiting compound, belapectin (GR-MD-02). Dr. Harold Shlevin, who is retiring from the CEO position, has signed a consulting agreement through which he has agreed to devote significant effort to advancing the NASH-RX trial. Dr. Shlevin and Mr. Lewis will retain their positions on Galectin’s Board of Directors. On the subject of the Board, because Joel will assume the role of CEO and President, he can no longer serve as Chairman of the Audit Committee.